"Advanced head and neck cancer" trang 1 - tải miễn phí từ tailieunhanh
Relevance of the time interval between surgery and adjuvant radio (chemo) therapy in HPV-negative and advanced head and neck carcinoma of unknown primary (CUP)

Relevance of the time interval between surgery and adjuvant radio (chemo) therapy in HPV-negative and advanced head and neck carcinoma of unknown primary (CUP)
10    51    1
Feasibility of concomitant cisplatin with hypofractionated radiotherapy for locally advanced head and neck squamous cell carcinoma

Feasibility of concomitant cisplatin with hypofractionated radiotherapy for locally advanced head and neck squamous cell carcinoma
9    83    0
Treatment strategy and outcomes in locally advanced head and neck squamous cell carcinoma: A nationwide retrospective cohort study (KCSG HN13–01)

Treatment strategy and outcomes in locally advanced head and neck squamous cell carcinoma: A nationwide retrospective cohort study (KCSG HN13–01)
9    45    1
Causes of death in patients with locally advanced head and neck cancer treated with radiotherapy and systemic therapy

Causes of death in patients with locally advanced head and neck cancer treated with radiotherapy and systemic therapy
10    84    1
Radiotherapy related skin toxicity (RAREST-01): Mepitel® film versus standard care in patients with locally advanced head-and-neck cancer

Radiotherapy related skin toxicity (RAREST-01): Mepitel® film versus standard care in patients with locally advanced head-and-neck cancer
5    74    1
Risk factors for aspiration pneumonia after definitive chemoradiotherapy or bioradiotherapy for locally advanced head and neck cancer: A monocentric case control study

Risk factors for aspiration pneumonia after definitive chemoradiotherapy or bioradiotherapy for locally advanced head and neck cancer: A monocentric case control study
11    49    1
Subcellular localisation of pMEK has a different prognosis in locally advanced head and neck cancer treated with concomitant radiochemotherapy

Subcellular localisation of pMEK has a different prognosis in locally advanced head and neck cancer treated with concomitant radiochemotherapy
8    30    1
CYP39A1 polymorphism is associated with toxicity during intensive induction chemotherapy in patients with advanced head and neck cancer

CYP39A1 polymorphism is associated with toxicity during intensive induction chemotherapy in patients with advanced head and neck cancer
7    78    1
Dose-dense TPF induction chemotherapy for locally advanced head and neck cancer: A phase II study

Dose-dense TPF induction chemotherapy for locally advanced head and neck cancer: A phase II study
9    41    1
Prophylactic gastrostomy in locally advanced head and neck cancer: Results of a national survey among radiation oncologists

Prophylactic gastrostomy in locally advanced head and neck cancer: Results of a national survey among radiation oncologists
8    44    1
Prediction of residual disease using circulating DNA detection after potentiated radiotherapy for locally advanced head and neck cancer (NeckTAR): A study protocol for a prospective, multicentre trial

Prediction of residual disease using circulating DNA detection after potentiated radiotherapy for locally advanced head and neck cancer (NeckTAR): A study protocol for a prospective, multicentre trial
7    1    1
Treatment patterns of targeted and nontargeted therapies and survival effects in patients with locally advanced head and neck cancer in Taiwan

Treatment patterns of targeted and nontargeted therapies and survival effects in patients with locally advanced head and neck cancer in Taiwan
12    6    1
HSP90 inhibition sensitizes head and neck cancer to platin-based chemoradiotherapy by modulation of the DNA damage response resulting in chromosomal fragmentation

HSP90 inhibition sensitizes head and neck cancer to platin-based chemoradiotherapy by modulation of the DNA damage response resulting in chromosomal fragmentation
13    33    1
Predictive and prognostic value of PET/CT imaging post-chemoradiotherapy and clinical decision-making consequences in locally advanced head & neck squamous cell carcinoma: A retrospective study

Predictive and prognostic value of PET/CT imaging post-chemoradiotherapy and clinical decision-making consequences in locally advanced head & neck squamous cell carcinoma: A retrospective study
9    47    1
Comparison of weekly administration of cisplatin versus three courses of cisplatin 100 mg/m2 for definitive radiochemotherapy of locally advanced head-and-neck cancers

Comparison of weekly administration of cisplatin versus three courses of cisplatin 100 mg/m2 for definitive radiochemotherapy of locally advanced head-and-neck cancers
8    45    1
Multicenter phase II study of weekly docetaxel, cisplatin, and S-1 (TPS) induction chemotherapy for locally advanced squamous cell cancer of the head and neck

Multicenter phase II study of weekly docetaxel, cisplatin, and S-1 (TPS) induction chemotherapy for locally advanced squamous cell cancer of the head and neck
9    46    2
Predictive factors of toxicity of TPF induction chemotherapy for locally advanced head and neck cancers

Predictive factors of toxicity of TPF induction chemotherapy for locally advanced head and neck cancers
9    25    1
Induction chemotherapy combined with immunotherapy in locally advanced head and neck squamous cell carcinoma

Induction chemotherapy combined with immunotherapy in locally advanced head and neck squamous cell carcinoma
9    45    1
Incidence and risk factors for acute kidney injury in head and neck cancer patients treated with concurrent chemoradiation with high-dose cisplatin

Incidence and risk factors for acute kidney injury in head and neck cancer patients treated with concurrent chemoradiation with high-dose cisplatin
10    88    0
A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer

A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer
11    70    1